We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Influence of Sodium Bicarbonate on Time-to-exhaustion at Critical Power in Endurance Athletes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01621074
Recruitment Status : Completed
First Posted : June 15, 2012
Last Update Posted : April 12, 2013
Sponsor:
Collaborator:
Swiss Federal Institute of Technology
Information provided by (Responsible Party):
University of Zurich

Brief Summary:
During endurance exercise in the heavy and severe intensity domains, the rate at which metabolites that have been associated with the fatigue process (e.g. Pi, ADP, H, and extracellular K) accumulate increases. possibly leading to exercise cessation. Sodium bicarbonate, as a nutritional supplement, has gained attention over the past decades, because it might delay of offset fatigue. To date, there is a controversial discussion about which delivery mode (amount and frequency) might be best in optimizing endurance performance. Since the high ion load consequent to multiple ingestions might increase plasma volume, and consequently decrease bicarbonate concentrations, single acute ingestion could be more beneficial. However, in multi-day competitions or tournaments it might be necessary to use the supplement on a daily basis. Here, the investigators aim at investigating the effects of single dose or multiple dose (on five consecutive days) administration of bicarbonate vs. placebo increases endurance performance and acid-base homeostasis in trained male endurance athletes.

Condition or disease Intervention/treatment
Performance Dietary Supplement: Sodium bicarbonate Dietary Supplement: Placebo

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Study Start Date : October 2011
Primary Completion Date : August 2012
Study Completion Date : January 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Sodium bicarbonate Dietary Supplement: Sodium bicarbonate
Ergogenic effect
Placebo Comparator: Placebo Dietary Supplement: Placebo
Placebo effect



Primary Outcome Measures :
  1. Time-to-exhaustion [ Time Frame: 5 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria: - male

  • no cold or temperature at beginning or during the study
  • between 18 and 45 years of age
  • active in endurance sports (3 to 5 times per week a moderate to hart training)
  • non-smoker
  • no known cardiovascular or orthopedic problems
  • no known limitations of kidney function
  • no bearer of a cardiac pacemaker
  • no medications with direct influence on the measurements. The whole intake of medicaments has to be declared in the health questionnaire by the participant.
  • requirements of the health questionnaire fulfilled

Exclusion criteria: - female

  • male and age under 18 or over 45 years
  • cold or temperature at the beginning or during the study
  • untrained (less than 3 moderate trainings per week)
  • smoker
  • cardiovascular or orthopedic problems
  • limitations of the kidney function
  • bearer of a cardiac pacemaker
  • medication with direct influence on the measurements. The whole intake of medicaments has to be declared in the health questionnaire by the participant.
  • requirements of the health questionnaire not fulfilled

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01621074


Locations
Switzerland
University Hospital Zurich, Division of Neurology
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Swiss Federal Institute of Technology
Investigators
Study Director: Neurologie: Neurologische Forschung University Hospital Zurich, Division of Neurology
Principal Investigator: Marco Toigo, PhD Swiss Federal Institute of Technology Zurich

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT01621074     History of Changes
Other Study ID Numbers: nbc
First Posted: June 15, 2012    Key Record Dates
Last Update Posted: April 12, 2013
Last Verified: April 2013